MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports.
Other equities analysts have also recently issued research reports about the company. Oppenheimer assumed coverage on MoonLake Immunotherapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $104.00 price objective for the company. Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research note on Monday, August 26th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, September 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.45.
Read Our Latest Stock Report on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Stock Down 2.1 %
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same quarter last year, the business posted ($0.23) EPS. As a group, equities analysts expect that MoonLake Immunotherapeutics will post -1.45 EPS for the current fiscal year.
Hedge Funds Weigh In On MoonLake Immunotherapeutics
Institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $51,000. Bellevue Group AG acquired a new stake in shares of MoonLake Immunotherapeutics in the first quarter valued at approximately $221,000. PNC Financial Services Group Inc. raised its position in MoonLake Immunotherapeutics by 50.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock worth $371,000 after purchasing an additional 2,067 shares during the last quarter. DNB Asset Management AS lifted its stake in shares of MoonLake Immunotherapeutics by 29.8% during the second quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock valued at $324,000 after acquiring an additional 1,694 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter worth approximately $726,000. 93.85% of the stock is owned by institutional investors.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
- Five stocks we like better than MoonLake Immunotherapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Following Congress Stock Trades
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Business Services Stocks Investing
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.